Nature Reviews Cardiology自然综述：心脏病学
Nature Reviews Cardiology(英文缩写 NAT REV CARDIOL),ISSN 1759-5002,eISSN 1759-5010,中文译名:自然综述：心脏病学 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 49.421 | Q1 |
| 2022 | 49.600 | Q1 |
| 2023 | 41.700 | Q1 |
| 2024 | 44.200 | Q1 |
| 2025 | 50.200 | Q1 |
Nature Reviews Cardiology 最新收录文献
-
1. Beating the odds: bringing the human heart into a dish.
1. 战胜逆境：将人类心脏带入培养皿PMID:日期:2026-09-17该文献暂无摘要。
-
2. Benefit of aficamten in non-obstructive hypertrophic cardiomyopathy.
2. 阿夫凯泰在非梗阻性肥厚型心肌病中的获益PMID:日期:2026-09-16该文献暂无摘要。
-
4. Tricuspid valve repair reduces death and HF hospitalization.
4. 三尖瓣修复术可降低死亡和心力衰竭住院率PMID:日期:2026-09-15该文献暂无摘要。
-
5. Pulmonary artery denervation shows promising results for heart failure-related pulmonary hypertension.
5. 肺动脉去神经术在治疗心力衰竭相关肺动脉高压方面显示出有希望的结果PMID:日期:2026-09-15该文献暂无摘要。
-
6. Fishing for answers: omega-3 fatty acids and cardiovascular health.
6. 探寻答案：欧米伽-3脂肪酸与心血管健康PMID:日期:2026-09-03该文献暂无摘要。
-
8. Dyslipidaemia and hepatic steatosis: mechanisms and implications for lipid-lowering therapy.
8. 血脂异常与肝脂肪变性：机制及对降脂治疗的意义PMID:日期:2026-08-27Dyslipidaemia and hepatic steatosis are interconnected metabolic disorders, often associated with obesity and diabetes mellitus, that contribute to the burden of cardiovascular disease. Hepatic steatosis is now recognized as a specific subset of metabolic dysfunction-associated steatotic liver disease (MASLD). Several processes contribute to lipid deposition in the liver, including increased de novo lipogenesis, impaired fatty acid oxidation and reduced lipoprotein biosynthesis. Hepatic lipid accumulation can also result from lipid-lowering therapies that impair lipoprotein production, thus requiring careful monitoring of hepatic lipid content in patients taking these medications. By contrast, drugs that lower plasma levels of lipids by increasing hepatic expression of the LDL receptor do not lead to lipid accumulation in the liver; however, some patients are less responsive than others to these therapies. Therefore, new therapeutics that decrease lipoprotein production without causing steatosis are needed. Indeed, balanced modulation of hepatic lipoprotein production and secretion, as well as systemic and cellular lipid catabolism, is crucial for hepatic lipid homeostasis. Strategies that target both plasma and hepatic lipid levels will help to reduce the burden of atherosclerosis and MASLD. In this Review, we discuss mechanistic links between dyslipidaemia and hepatic steatosis, emphasizing lipid-lowering therapies and their effects on hepatic lipid accumulation.
-
9. Reply to 'Bedside epicardial adipose tissue assessment in the era of advanced adipose phenotyping'.
9. 回复“先进脂肪表型分析时代的床旁心外膜脂肪组织评估”PMID:日期:2026-08-27该文献暂无摘要。
-
10. Bedside epicardial adipose tissue assessment in the era of advanced adipose phenotyping.
10. 先进脂肪表型分析时代的床旁心外膜脂肪组织评估PMID:日期:2026-08-27该文献暂无摘要。